Advertisement

Topics

TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

2014-08-27 03:55:34 | BioPortfolio

Summary

This is a dose-ranging, open-label, Phase 1-2a study of TLK286 in combination with Doxil in patients with platinum refractory or resistant ovarian cancer.

Study Design

Allocation: Non-Randomized, Control: Uncontrolled, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Conditions

Ovarian Neoplasms

Intervention

TLK286

Location

M.D. Anderson Cancer Center
Houston
Texas
United States
77030

Status

Completed

Source

Telik

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-08-27T03:55:34-0400

Clinical Trials [1141 Associated Clinical Trials listed on BioPortfolio]

Phase 2 Study of TLK286 in Platinum Resistant Advanced Epithelial Ovarian Cancer

The purpose of this study is to determine the effectiveness and safety of TLK286 given intravenously once every week in the treatment of patients with advanced ovarian cancer that is resis...

TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

This is a dose-ranging, open label, Phase 1-2a study of TLK286 in combination with Paraplatin (carboplatin) in patients with recurrent ovarian cancer.

TLK286 (Telcyta) vs. Doxil/Caelyx or Hycamtin in Platinum Refractory or Resistant Ovarian Cancer

The purpose of this study is to demonstrate superiority in survival in favor of TLK286 as compared to active control therapy with Doxil/Caelyx or Hycamtin in the intent-to-treat (ITT) popu...

Phase 2 Study of TLK286 in Metastatic Breast Cancer

The purpose of this study is to determine the effectiveness of TLK286 in treatment of metastatic breast cancer.

TLK286 in Treating Patients With Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of TLK286 in tre...

PubMed Articles [1534 Associated PubMed Articles listed on BioPortfolio]

Ovarian tumors secreting androgens: an infrequent cause of hyperandrogenism.

The sex cord-stromal tumors are relative rare, comprising 5-8% of all ovarian neoplasms.

Role of Alpha-Smooth Muscle Actin and Fibroblast Activation Protein Alpha in Ovarian Neoplasms.

Studies show that tumor growth is not just determined by the presence of malignant cells, since interactions between cancer cells and stromal microenvironment have important impacts on the cancer grow...

Primary fallopian tube sex cord tumour: Tubal counterpart of uterine tumour resembling ovarian sex cord tumour.

Uterine tumour resembling ovarian sex cord tumour (UTROSCT) is an uncommon mesenchymal neoplasm which morphologically resembles and expresses markers of ovarian sex cord-stromal tumours (1,2). It has ...

Cysteine allows ovarian cancer cells to adapt to hypoxia and to escape from carboplatin cytotoxicity.

Ovarian cancer is the second most common gynaecologic malignancy and the main cause of death from gynaecologic cancer, due to late diagnosis and chemoresistance. Studies have reported the role of cyst...

NF2 and ATRX gene copy number losses on a case of ovarian ependymoma.

Ovarian ependymomas are rare glial neoplasms that typically occur in females on their 3rd to 4th decade of life. They are histologically similar to ependymomas of the central nervous system (CNS) but ...

Medical and Biotech [MESH] Definitions

Hereditary nonpolyposis colorectal neoplasms associated with other malignancies, more commonly of ovarian or uterine origin. When also associated with SEBACEOUS GLAND NEOPLASMS, it is called MUIR-TORRE SYNDROME.

Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.

Diseases involving the FALLOPIAN TUBES including neoplasms (FALLOPIAN TUBE NEOPLASMS); SALPINGITIS; tubo-ovarian abscess; and blockage.

Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.

Cessation of ovarian function after MENARCHE but before the age of 40, without or with OVARIAN FOLLICLE depletion. It is characterized by the presence of OLIGOMENORRHEA or AMENORRHEA, elevated GONADOTROPINS, and low ESTRADIOL levels. It is a state of female HYPERGONADOTROPIC HYPOGONADISM. Etiologies include genetic defects, autoimmune processes, chemotherapy, radiation, and infections.

More From BioPortfolio on "TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Ovarian Cancer
Ovarian Cancer is cancer that starts in the female reproductive organs, the ovaries. It is the fifth most common cancer among women.  Women at risk of Ovarian Cancer are those who have had few children (or had children at an older age), carriers o...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...


Searches Linking to this Trial